- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Obinutuzumab – July 2018
Obinutuzumab: Solution for I.V. infusion 1000 mg in 40 mL; Gazyva®
Last updated
26 October 2018